Citations

Mayo Clinic

Showing 10 of 108572 citations.

Safety and efficacy of glucagon-like peptide-1 receptor agonists among kidney transplant recipients: a systematic review and meta-analysis
Sanpawithayakul, Kanokporn , Tangpanithandee, Supawit , Miao, Jing , Cheungpasitporn, Wisit , Sanpawithayakul, Kanokporn , Cheungpasitporn, Wisit , Tangpanithandee, Supawit , Miao, Jing , Krisanapan, Pajaree , Suppadungsuk, Supawadee , Thongprayoon, Charat , Pattharanitima, Pattharawin , Mao, Michael A.

Clinical Kidney Journal | February 1, 2024 | Volume: 17 | Issue: 2 | Pages: No page available

10.1093/ckj/sfae018 | PMID 38410684 Get It

ABSTRACT Background Evidence supporting glucagon-like peptide-1 receptor agonists (GLP-1RAs) in kidney transplant recipients (KTRs) remains scarce. This systematic review and meta-analysis aims to evaluate the safety and efficacy of GLP-1RAs in this population. Methods A comprehensive literature search was conducted in the MEDLINE, Embase and Cochrane databases from inception through May 2023. Clinical trials and observational studies that reported on the safety or efficacy outcomes of GLP-1RAs in adult KTRs were included. Kidney graft function, glycaemic and metabolic parameters, weight, cardiovascular outcomes and adverse events were evaluated. Outcome measures used for analysis included pooled odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous outcomes and standardized mean difference (SMD) or mean difference (MD) with 95% CI for continuous outcomes. The protocol was registered in the International Prospective Register of Systematic Reviews (CRD 42023426190). Results Nine cohort studies with a total of 338 KTRs were included. The median follow-up was 12 months (interquartile range 6–23). While treatment with GLP-1RAs did not yield a significant change in estimated glomerular filtration rate [SMD −0.07 ml/min/1.73 m2 (95% CI −0.64–0.50)] or creatinine [SMD −0.08 mg/dl (95% CI −0.44–0.28)], they were associated with a significant decrease in urine protein:creatinine ratio [SMD −0.47 (95% CI −0.77 to −0.18)] and haemoglobin A1c levels [MD −0.85% (95% CI −1.41 to −0.28)]. Total daily insulin dose, weight and body mass index also decreased significantly. Tacrolimus levels remained stable [MD −0.43 ng/ml (95% CI −0.99 to 0.13)]. Side effects were primarily nausea and vomiting (17.6%), diarrhoea (7.6%) and injection site pain (5.4%). Conclusions GLP-1RAs are effective in reducing proteinuria, improving glycaemic control and supporting weight loss in KTRs, without altering tacrolimus levels. Gastrointestinal symptoms are the main side effects.
Comparative Analysis of Two Hemiarthroplasty Techniques for Symptomatic Distal Radial Ulnar Joint Arthritis
Hebel, Nathan , Wu, Kitty Y. , Helsper, Elizabeth, Hassan, Bassem El, Rizzo, Marco , Moran, Steven L. , El Hassan, Bassem, Kakar, Sanjeev

Journal of Wrist Surgery | January 31, 2024 | Volume: 14 | Issue: 02 | Pages: 144-150

10.1055/s-0044-1779498 | PMID 40151782 Get It

Abstract Background Hemiarthroplasty may be indicated for patients with distal radioulnar joint (DRUJ) arthritis. Recently, the use of the pyrocarbon metacarpophalangeal implant has been proposed as a novel means of treating DRUJ arthritis due to the materials improved mechanical properties and wear characteristics. Purpose This study compares midterm outcomes of metallic and pyrocarbon hemiarthroplasties for the treatment of symptomatic DRUJ arthritis. Questions of interest included outcomes and complications. Materials and Methods In total, 32 hemiarthroplasties, 10 metallic and 22 pyrocarbon, were performed between 2010 and 2020 by three surgeons at one tertiary medical center. Patients' retrospective outcomes were extracted from the electronic medical record. Results Postoperatively, the metallic implant group (mean follow-up: 38 months) demonstrated decreased pain but no changes in range of motion. Comparatively, the pyrocarbon group experienced an improved range of motion and postoperative pain (p < 0.05). Radiographic analysis demonstrated 10% of metallic implants and 9% of pyrocarbon implants to have resulted in thinning of the lateral cortex of the radius at the final follow-up. Minor complications in metallic and pyrocarbon implant groups warranting reoperation occurred at rates of 10 and 13.5% while implant failure occurred at a rate of 30 and 18%, respectively. Discussion Within this study, pyrocarbon implants resulted in significant functional improvement with comparable complication and failure rates to the metallic implant. Long-term stability demonstrated efficacy for both techniques in symptomatic DRUJ treatment. Type of Study/Level of Evidence Observational Case Series IV.
Neonatal hemophagocytic lymphohistiocytosis: A meta‐analysis of 205 cases
Kranz, Lincoln A., Hahn, Wyatt S., Hentz, Roland, Kobrinsky, Nathan L. , Galardy, Paul J. , Greenmyer, Jacob R. , Thompson, Whitney S. , Galardy, Paul J , Greenmyer, Jacob R

Pediatric Blood & Cancer | January 31, 2024 | Volume: 71 | Issue: 4 | Pages: No page available

10.1002/pbc.30894 | PMID 38296838 Get It

Abstract Background Neonatal hemophagocytic lymphohistiocytosis (nHLH), defined as HLH that presents in the first month of life, is clinically devastating. There have been few large descriptive studies of nHLH. Objectives The objective of this study was to perform a meta‐analysis of published cases of nHLH. Methods A comprehensive literature database search was performed. Cases of HLH were eligible for inclusion if clinical analysis was performed at age ≤30 days. Up to 70 variables were extracted from each case. Results A total of 544 studies were assessed for eligibility, and 205 cases of nHLH from 142 articles were included. The median age of symptom onset was day of life 3 (interquartile range [IQR]: 0–11, n = 141). Median age at diagnosis was day of life 15 (IQR: 6–27, n = 87). Causes of HLH included familial HLH (48%, n = 99/205), infection (26%, n = 53/205), unknown (17%, n = 35/205), macrophage activation syndrome/rheumatologic (2.9%, n = 4/205), primary immune deficiency (2.0%, n = 5/205), inborn errors of metabolism (2.4%, n = 5/205), and malignancy (2.0%, n = 4/205). Fever was absent in 19% ( n = 28/147) of all neonates and 39% ( n = 15/38) of preterm neonates. Bicytopenia was absent in 26% ( n = 47/183) of patients. Central nervous system (CNS) manifestations were reported in 63% of cases ( n = 64/102). Liver injury (68%, n = 91/134) and/or liver failure (24%, n = 32/134) were common. Flow cytometry was performed in 22% ( n = 45/205) of cases. Many patients (63%, n = 121/193) died within the period of reporting. Discernable values for HLH diagnostic criteria were reported between 30% and 83% of the time. Conclusions Evaluation of nHLH requires rapid testing for a wide range of differential diagnoses. HLH diagnostic criteria such as fever and bicytopenia may not occur as frequently in the neonatal population as in older pediatric populations. Neurologic and hepatic manifestations frequently occur in the neonatal population. Current reports of nHLH suggest a high mortality rate. Future publications containing data on nHLH should improve reporting quality by reporting all clinically relevant data.
Response to: Comment on: COG Diagnostic Imaging Committee/SPR Oncology Committee White Papers
Towbin, Alexander J. , Tang, Elizabeth , Thacker, Paul G. , McCarville, M. Beth , Thacker, Paul G , Alazraki, Adina

Pediatric Blood & Cancer | January 31, 2024 | Volume: 71 | Issue: 4 | Pages: No page available

10.1002/pbc.30900 | PMID 38296784 Get It

Flipping the Switch
Finta, Mary K. , Albin, Owen , Ghani, Khurshid R. , Dhaliwal, Gurpreet, Albin, Owen , Houchens, Nathan, Dhaliwal, Gurpreet , Houchens, Nathan

New England Journal of Medicine | January 31, 2024 | Volume: 390 | Issue: 5 | Pages: 456-462

10.1056/nejmcps2307875 | PMID 38294978 Get It

From the Front Lines: The Need for Stakeholder Coalitions in Preserving Reproductive Autonomy
McGowan, Michelle L. , Allyse, Megan , Condon, Niamh, Wheatley, Jason P., Pensak, Meredith J., Allyse, Megan A

The American Journal of Bioethics | January 31, 2024 | Volume: 24 | Issue: 2 | Pages: 46-48

10.1080/15265161.2023.2296405 | PMID 38295260 Get It

Hand Movement Velocity Estimation From WiFi Channel State Information
Hasanzadeh, Navid , Djogo, Radomir , Salehinejad, Hojjat , Valaee, Shahrokh

2023 IEEE 9th International Workshop on Computational Advances in Multi-Sensor Adaptive Processing (CAMSAP) | January 31, 2024 | Volume: No volume available | Issue: No issue available | Pages: 296-300

10.1109/camsap58249.2023.10403438 Get It

Bariatric Surgery and Longitudinal Cancer Risk
Lim, Pei‐Wen , Stucky, Chee‐Chee , Wasif, Nabil , Etzioni, David A. , Harold, Kristi L., Madura, James A., Ven Fong, Zhi, Fong, Zhi Ven

JAMA Surgery | January 31, 2024 | Volume: 159 | Issue: 3 | Pages: 331

10.1001/jamasurg.2023.5809 | PMID 38294801 Get It

ImportanceCancer is one of the leading causes of death in the United States, with the obesity epidemic contributing to its steady increase every year. Recent cohort studies find an association between bariatric surgery and reduced longitudinal cancer risk, but with heterogeneous findings.ObservationsThis review summarizes how obesity leads to an increased risk of developing cancer and synthesizes current evidence behind the potential for bariatric surgery to reduce longitudinal cancer risk. Overall, bariatric surgery appears to have the strongest and most consistent association with decreased incidence of developing breast, ovarian, and endometrial cancers. The association of bariatric surgery and the development of esophageal, gastric, liver, and pancreas cancer is heterogenous with studies showing either no association or decreased longitudinal incidences. Conversely, there have been preclinical and cohort studies implying an increased risk of developing colon and rectal cancer after bariatric surgery. A review and synthesis of the existing literature reveals epidemiologic shortcomings of cohort studies that potentially explain incongruencies observed between studies.Conclusions and RelevanceStudies examining the association of bariatric surgery and longitudinal cancer risk remain heterogeneous and could be explained by certain epidemiologic considerations. This review provides a framework to better define subgroups of patients at higher risk of developing cancer who would potentially benefit more from bariatric surgery, as well as subgroups where more caution should be exercised.
Considerations for the treatment of frail multiple myeloma patients
Mohty, Mohamad , Rajkumar, S. Vincent

Clinical Hematology International | January 31, 2024 | Volume: 6 | Issue: 1 | Pages: No page available

10.46989/001c.92586 | PMID 38817702 Get It

Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA
Ailawadhi, Sikander , Ravelo, Arliene , Ng, Carmen D. , Shah, Bonny, Lamarre, Neil, Wang, Rongrong , Eakle, Katherine, Biondo, Juliana ML, Ailawadhi, Sikander , Biondo, Juliana M.L.

Journal of Comparative Effectiveness Research | January 31, 2024 | Volume: 13 | Issue: 2 | Pages: No page available

10.57264/cer-2023-0119 | PMID 38294335 Get It

Aim: Improved management of chronic lymphocytic leukemia (CLL) has resulted in a growing population of CLL survivors; these patients have a higher risk of developing second primary malignancies (SPMs) versus the general population. This retrospective cohort study aims to assess the timing, frequency, incidence and types of SPMs in treated and untreated patients with CLL in the USA, using the Surveillance, Epidemiology, and End Results (SEER) Medicare database, which links a nationally representative cancer registry with Medicare claims data. Patients & methods: Patients aged ≥66 years with newly diagnosed CLL between 1 January 2010 and 31 December 2016, who were enrolled in Parts A and B of Medicare for ≥12 months pre-diagnosis of CLL were selected from the database. Patients were assessed for ≥36 months until the end of continuous enrollment in Medicare Parts A, B and D, a switch to a health maintenance organization, death, or end of the study period (December 2019). Results: Of 3053 patients included in the analyses, 620 (20.3%) were treated and 2433 (79.7%) were untreated within 36 months of diagnosis. Overall, 638 (20.9%) patients developed a SPM, 26.8% of patients in the treated cohort and 19.4% of patients in the untreated cohort. The most common SPMs for both cohorts were squamous cell carcinoma and acute myeloid leukemia. Among the 166 treated patients who developed a SPM, a greater proportion developed their first SPM after treatment initiation versus those who developed their first SPM prior to treatment initiation (p < 0.001). A significantly lower percentage of patients who received targeted therapy developed a SPM (p < 0.05) versus patients treated with anti-CD20 + chemotherapy. Conclusion: Findings indicate that treatment type and timing can affect SPM development in patients with CLL. Combined with previous findings, this can help inform best practices in monitoring for SPM in patients with CLL.